CN101524348A - 茶多酚在制备治疗肿瘤药剂中的应用 - Google Patents
茶多酚在制备治疗肿瘤药剂中的应用 Download PDFInfo
- Publication number
- CN101524348A CN101524348A CN200810034350A CN200810034350A CN101524348A CN 101524348 A CN101524348 A CN 101524348A CN 200810034350 A CN200810034350 A CN 200810034350A CN 200810034350 A CN200810034350 A CN 200810034350A CN 101524348 A CN101524348 A CN 101524348A
- Authority
- CN
- China
- Prior art keywords
- tea polyphenols
- cell
- application
- medicament
- egcg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 75
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 75
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 37
- 241001122767 Theaceae Species 0.000 title abstract 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 36
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 35
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 7
- 244000269722 Thea sinensis Species 0.000 claims description 76
- 235000013616 tea Nutrition 0.000 claims description 71
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 42
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 22
- 235000005487 catechin Nutrition 0.000 claims description 22
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 21
- 239000002775 capsule Substances 0.000 claims description 19
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims description 18
- 150000001765 catechin Chemical class 0.000 claims description 18
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims description 14
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 12
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001948 caffeine Drugs 0.000 claims description 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000009569 green tea Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 3
- 239000001263 FEMA 3042 Substances 0.000 claims description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 3
- 229940033123 tannic acid Drugs 0.000 claims description 3
- 235000015523 tannic acid Nutrition 0.000 claims description 3
- 229920002258 tannic acid Polymers 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 42
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 230000001413 cellular effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 94
- 230000006907 apoptotic process Effects 0.000 description 20
- 230000001640 apoptogenic effect Effects 0.000 description 16
- 238000002372 labelling Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 208000034578 Multiple myelomas Diseases 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 108010040476 FITC-annexin A5 Proteins 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108010077544 Chromatin Proteins 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 210000003483 chromatin Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000004660 morphological change Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229950001002 cianidanol Drugs 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 229940100691 oral capsule Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- -1 (EGCG) Chemical class 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 230000003156 vasculitic effect Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810034350A CN101524348A (zh) | 2008-03-06 | 2008-03-06 | 茶多酚在制备治疗肿瘤药剂中的应用 |
| JP2010549002A JP2011513340A (ja) | 2008-03-06 | 2009-03-05 | 腫瘍の予防または治療用医薬の製造における茶ポリフェノールの使用 |
| CN2009801045844A CN101965185A (zh) | 2008-03-06 | 2009-03-05 | 茶多酚在制备预防或治疗肿瘤药物中的应用 |
| PCT/CN2009/000233 WO2009109109A1 (zh) | 2008-03-06 | 2009-03-05 | 茶多酚在制备预防或治疗肿瘤药物中的应用 |
| EP09716802.5A EP2263668B1 (en) | 2008-03-06 | 2009-03-05 | Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors |
| US12/921,353 US20110021620A1 (en) | 2008-03-06 | 2009-03-05 | Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors |
| US13/941,584 US20130303604A1 (en) | 2008-03-06 | 2013-07-15 | Method of Using Tea Polyphenols for Prevention and Treatment of Malignant Tumors in a Hematopoietic System |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810034350A CN101524348A (zh) | 2008-03-06 | 2008-03-06 | 茶多酚在制备治疗肿瘤药剂中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101524348A true CN101524348A (zh) | 2009-09-09 |
Family
ID=41055542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810034350A Pending CN101524348A (zh) | 2008-03-06 | 2008-03-06 | 茶多酚在制备治疗肿瘤药剂中的应用 |
| CN2009801045844A Pending CN101965185A (zh) | 2008-03-06 | 2009-03-05 | 茶多酚在制备预防或治疗肿瘤药物中的应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801045844A Pending CN101965185A (zh) | 2008-03-06 | 2009-03-05 | 茶多酚在制备预防或治疗肿瘤药物中的应用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110021620A1 (https=) |
| EP (1) | EP2263668B1 (https=) |
| JP (1) | JP2011513340A (https=) |
| CN (2) | CN101524348A (https=) |
| WO (1) | WO2009109109A1 (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102580112A (zh) * | 2012-02-28 | 2012-07-18 | 南京农业大学 | Egcg磷脂复合物的制备方法 |
| WO2017008597A1 (zh) * | 2015-07-15 | 2017-01-19 | 福建农林大学 | 一种抑瘤功能茶树良种的选育方法 |
| CN107115337A (zh) * | 2017-07-06 | 2017-09-01 | 中国科学院上海有机化学研究所 | 一种儿茶素类化合物的应用 |
| CN119386097A (zh) * | 2024-10-31 | 2025-02-07 | 重庆市优胜科技发展有限公司 | 茶多酚在防治三阴性乳腺癌中的应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6592010B2 (ja) * | 2014-12-22 | 2019-10-16 | シーシーアイホールディングス株式会社 | 癌細胞増殖抑制組成物および癌細胞増殖の抑制方法 |
| US10380765B2 (en) * | 2016-08-17 | 2019-08-13 | Magna Electronics Inc. | Vehicle vision system with camera calibration |
| CN111944771B (zh) * | 2019-10-29 | 2022-06-14 | 华南农业大学 | 茶多酚或其组分在制备粪肠球菌噬菌体钝化剂中的应用 |
| CN115887443A (zh) * | 2023-02-27 | 2023-04-04 | 深圳市第二人民医院(深圳市转化医学研究院) | 表没食子儿茶素在制备结直肠癌治疗药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410052B1 (en) * | 1999-03-30 | 2002-06-25 | Purdue Research Foundation | Tea catechins in sustained release formulations as cancer specific proliferation inhibitors |
| US6428818B1 (en) * | 1999-03-30 | 2002-08-06 | Purdue Research Foundation | Tea catechin formulations and processes for making same |
| JP3525182B2 (ja) * | 2000-02-16 | 2004-05-10 | 独立行政法人産業技術総合研究所 | 新規抗白血病細胞剤 |
| US7192612B2 (en) * | 2001-02-22 | 2007-03-20 | Purdue Research Foundation | Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer |
| JP2005075790A (ja) * | 2003-09-02 | 2005-03-24 | Fumio Hashimoto | Ａｐｏｐｔｏｓｉｓ誘導剤 |
-
2008
- 2008-03-06 CN CN200810034350A patent/CN101524348A/zh active Pending
-
2009
- 2009-03-05 CN CN2009801045844A patent/CN101965185A/zh active Pending
- 2009-03-05 JP JP2010549002A patent/JP2011513340A/ja active Pending
- 2009-03-05 EP EP09716802.5A patent/EP2263668B1/en active Active
- 2009-03-05 WO PCT/CN2009/000233 patent/WO2009109109A1/zh not_active Ceased
- 2009-03-05 US US12/921,353 patent/US20110021620A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102580112A (zh) * | 2012-02-28 | 2012-07-18 | 南京农业大学 | Egcg磷脂复合物的制备方法 |
| WO2017008597A1 (zh) * | 2015-07-15 | 2017-01-19 | 福建农林大学 | 一种抑瘤功能茶树良种的选育方法 |
| CN107115337A (zh) * | 2017-07-06 | 2017-09-01 | 中国科学院上海有机化学研究所 | 一种儿茶素类化合物的应用 |
| CN119386097A (zh) * | 2024-10-31 | 2025-02-07 | 重庆市优胜科技发展有限公司 | 茶多酚在防治三阴性乳腺癌中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011513340A (ja) | 2011-04-28 |
| WO2009109109A1 (zh) | 2009-09-11 |
| US20110021620A1 (en) | 2011-01-27 |
| EP2263668A1 (en) | 2010-12-22 |
| CN101965185A (zh) | 2011-02-02 |
| EP2263668A4 (en) | 2012-05-09 |
| EP2263668B1 (en) | 2014-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101524348A (zh) | 茶多酚在制备治疗肿瘤药剂中的应用 | |
| CN110063953A (zh) | 一种治疗子宫内膜癌的药物组合物 | |
| CN102688501A (zh) | 原花青素b2磷脂复合物及其制备方法和用途 | |
| CN106166149B (zh) | 银杏双黄酮的应用 | |
| CN105769891A (zh) | 低极性稀有人参皂苷混合物及其用途 | |
| CN106619588B (zh) | 一种含辅酶q10的自微乳型营养组合物、制备方法及用途 | |
| Mittal et al. | Plant extracts with antioxidant and hepatoprotective benefits for liver health: A bibliometric analysis of drug delivery systems | |
| CN111481640B (zh) | 抗肝癌微乳纳米组合物及其应用 | |
| CN101912377A (zh) | 紫檀芪在制备抗宫颈癌药物中的应用 | |
| US20130303604A1 (en) | Method of Using Tea Polyphenols for Prevention and Treatment of Malignant Tumors in a Hematopoietic System | |
| Deepthi et al. | Evaluation of cytotoxic potential of Digera muricata leaf extract on lung cancer cell line | |
| CN103565849A (zh) | 一种含螺旋藻的胶囊及其制备方法 | |
| Khosropour et al. | Antimalarial Response, Traditional and Other Potential Uses of Cinchona Genera | |
| CN101342179A (zh) | 一种抗肿瘤的中药制品及其制备方法 | |
| CN110063988A (zh) | 一种治疗神经母细胞瘤的药物组合物及其制备方法 | |
| Sowińska et al. | “Silybum marianum”–properties and application in medicine–a review | |
| CN104997787A (zh) | 甘草次酸在制备抗辐射产品中的应用 | |
| CN102283948A (zh) | 一种五味消毒饮整合型新剂型制备技术及其生产方法 | |
| CN112245444A (zh) | 圣草次苷在制备抑制心血管疾病药物中的应用 | |
| CN110151824A (zh) | 一种治疗下咽癌的药物组合物及其制备方法 | |
| CN102440994A (zh) | 灵芝酸g在肿瘤治疗中作为免疫增效剂和超抗原依赖的治疗药物的应用 | |
| CN110859830B (zh) | 一种含有苯并氢化吡喃醇衍生物与茜草素型蒽醌类化合物的组合物及其剂型与用途 | |
| CN109602775B (zh) | 乳苣醇提物在制备抗乳腺癌药物中的用途 | |
| CN108096239A (zh) | 一种治疗脑胶质瘤和肝癌的药物组合物 | |
| CN100584352C (zh) | 五味子及其提取物在制备治疗肿瘤多药耐药药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090909 |